CAR-T therapy with stem cell transplant for leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a treatment plan for people with acute leukemia that has come back or not responded to treatment. It combines CAR-T therapy with a stem cell transplant from a half-matched donor and special immune cell infusions to help prevent relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute leukemia that has returned or not responded to standard treatment.
- You do not have a fully matched sibling or unrelated donor available.
- After CAR-T therapy, your leukemia is in remission and no cancer cells are found in your bone marrow or elsewhere.
- Your liver, kidney, and heart function are within acceptable limits.
- You are able to provide signed consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
This trial tests a combination of CAR-T cell therapies (targeting CD123, CLL-1, and CD7) followed by a stem cell transplant for people with acute myeloid leukemia that has returned or not improved. The goal is to see if this approach can help eliminate the leukemia and prepare for a transplant.
This trial tests giving special immune cells (CAR T cells) after a half-matched stem cell transplant. It's for children and young adults with high-risk leukemia or lymphoma that has come back or not responded to treatment.
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.